Table 7 Results of the base case cost-effectiveness analysis (year 2010 values) from the social health insurance perspective (standard errors in parentheses)
Type of surgery | Costs (€) | Incremental costs (€) | VTE events per person | Incremental effect(events avoided) | ICER(€ per event avoided) |
|---|---|---|---|---|---|
THR | |||||
Rivaroxaban | 146.5 (14.2) | 17.8 (19.6) | 0.005 (0.002) | 0.007 (0.005) | 875 |
Enoxaparin | 128.7 (14.9) | 0.012 (0.005) | |||
TKR | |||||
Rivaroxaban | 20.7 (9.0) | −27.3 (10.7) | 0.014 (0.005) | 0.020 (0.007) | dominant |
Enoxaparin | 48.0 (16.9) | 0.035 (0.009) |